Calcipotriol a review of its pharmacological properties and therapeutic efficacy in the management of psoriasis

Clinical Immunotherapeutics

Volumn 5, Issue 3, 1996, Pages 230-248

  Lea, Andrew P ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CALCIUM; COAL TAR; CYCLOSPORIN; DITHRANOL; FLUOCINONIDE; PSORALEN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; HOMEOSTASIS; HUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; REVIEW; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 0029927654     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259086     Document Type: Article

References (136)

1. Araujo OE, Flowers FP, Brown KB. Vitamin D therapy in psoriasis. DICP 1991 Jul-Aug; 25: 835-9
2. Murdoch D, Clissold SP. Calcipotriol: a review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 1992 Man 43: 415-29
3. MacLaughlin JA. Gange W. Taylor D, et al. Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial hut not absolute resistance to the proliferation-inhibition activity of 1,25-clihydroxyvitamin Di. Proc Natl Acad Sei USA 1985: 82: 5409-12
4. Morimoto S, Yoshikawa K, Kozuka T. et al. An open study of vitamin D.i treatment in psoriasis vulgaris. Br J Dermatol 1986; 115:421-9
5. Camp RDR. Psoriasis. In: Champion R, Burton J. Ebling FJG. editors. Textbook of dermatology. 5th ed. Oxford: Blackwell Scientific Publications. 1991: 1391-457
6. Kragballe K. Vitamin D analogues in the treatment ot psoriasis. J Cell Biochem 1992 May. 49: 46-52
7. Berg JP, Liane KM, Bj0rhovde SB, et al. Vitamin D receptor binding and biological effects of choleealciferol analogues in rat thyroid cells. J Steroid Biochem Mol Biol 1994 Aug: 50: 145-50
8. Binderup L. Comparison of calcipotriol with selected metabolites and analogues of vitamin D.<: effects on cell growth regulation in vitro and calcium metabolism i vivo. Pharmacol Toxicol 1993 Apr-May; 72: 240-4
9. Binderup L. Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988 Mar 1:37:889-95
10. Evans DB. Thavarajah M. Binderup L. et al. Actions of cal cipolriol (MC 903), a novel vitamin-Di analog, on human bone-derived cells: comparison with 1,25-dihydroxy vitaminDî. J Bone Miner Res 1991 Dec; 6: 1307-15
11. Limât A, Hunziker T, Braathen LR. Effects of l-a,25-dihydroxy-vitamin-Di and calcipotriol on organotypic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs. Arch Dermatol Res 1993 Oct: 285: 402-9
12. Trydal T. Lillehaug JR. Aksnes L, et al. Regulation of cell growth, r-mvc mRNA. and 1.25-(OH): vitamin Di receptor in C3H/10T1/2 mouse embryo tibroblasts by calcipotriol and 1,25-(OH); vitamin Di. Acta Endocrinol Copenh 1992 Jan; 126:75-9
13. Valaja T, Mahonen A. Pirskanen A. et al. Affinity of MC 903 for 1.25-dihydroxyvitamin D receptor and its effects on the synthesis of osteocalcin in human osteosarcoma cells. Biochem Pharmacol 1990 Oct 15; 40: 1827-32
14. dc Jong EM. van de Kerkhof PC. Simultaneous assessment ot inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D< analogue MC903: modulations and interrelations |see comments]. Br J Dermatol 1991 Mar; 124: 221-9
15. de Mare S, de Jong EG, van de Kerkhof PC. DNA content and K.,8.12 binding of the psoriatic lesion during treatment with the vitamin D-, analogue MC903 and betamethasone. Br J Dermatol !990Sep; 123: 291-5
16. Berth-Jones J, Fletcher A. Hutchinson PE. Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate. Br J Dermatol 1992 Apr; 126: 356-61
17. Gerritsen MJ, Rulo HF, van Vlijmen-Willems I. et al. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D;: a cell biological study. Br J Dermatol 1993 June: 12X (6): 666-73
18. Marie PJ. Connes D. Hott M. et al. Comparative effects of a novel \itamin D analogue MC-903 and 1.25-dihydroxyvitamin-D} on alkaline phosphatase activity, osteocalcin and DNA synthesis by human osteoblastic cells in culture. Bone 1990; 11 (3): 17l-9
19. Kragballe K. Wildfang IL. Calcipotriol (MC 903). a novel \itaniin Di analogue stimulates terminal differentiation and in hibits proliferation of eultured human keratinocytes. Arch Dermatol Res 1990; 282 (3): 164-7
20. Palleschi CM. Gentili A. Caproni M. et al. Structural alterations of basal keratinocytes and capillary loop in psoriasis during treatment with topical calcipotriol. Acta Derm Venereol 1994 Suppl. 186:49-51
21. Muller K. Svenson M. Bendtzen K. l Oc.25-Dihydroxyvitamin Dî and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Imtnunol Lett 1988 Apr: 17:361-5
22. Müller K. Diamant M. Bendtzen K. Inhibition of production and function of interleukin-6 by 1.25-dihydroxyvitamin D\. Immunol Lett 1991 May: 28: l i 5-20
23. Kemény L, Kenderessy AS. Olasz E. et al. The interleukin-8 receptor: a potential target for antipsoriatic therapy'.' Eur J Pharmacol 1994 Jun 13: 258: 269-72
24. Mozzanica N. Cattaneo A, Schmitt E. et al. Topical calcipotriol for psoriasis - an immunohistologic study. Acta Derm Venereol 1994; Suppl. 186: 171-2
25. Finzi AF. A controlled multicentre study comparing the efficacy and safety of calcipotriol with a combination of betametha sone dipropionate/salicylic acid (abstract]. Calcipotriol: a Vitamin D Analogue for the Treatment of Psoriasis. Satellite Symposium of the Third Congress of the European Academy of Dermatology and Venereology. Copenhagen. Sep 1993.
26. Cagnoni ML. Ghersetich I. Lotti T. et al. Treatment of psoriasis vulgaris with topical culcipotriol: is the clinical improvement of lesional skin related to a down-regulation of some cell adhesion molecules? Acta Derm Venereol 1994 Suppl. 186: 55-7
27. Koli K, Keski-Oja J. Vitamin D; and calcipotriol decrease ex tracellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 1993 Nov: 101: 706-12
28. Jehan F. Neveu I. Barbot N. et al. MC903. an analogue of 1,25dihydroxyvitamin D-., increases the synthesis of nerve growth factor. Eur J Pharmacol Mol Pharmacol 1991 Oct 14; 208: 189-91
29. Koli K. Keski-Oja J. Vitamin Di and calcipotriol enhance the secretion of transforming growth factor-pM and -|32 in cultured murine keratinocytes. Growth Factors 1993: X (2): 153-63
30. Koli K. Keski-Oja j. 1,25-dihydroxyvitamin Dî enhances the expression of transforming growth factor -1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 1995 Apr 1:55: 1540-6
31. Carlberg C. Mathiasen IS, Saurai J-H, et al. The 1.25 dihydroxyvitamin D; (VD) analogues MC903. EB1089 and KH1060 activate the VD receptor: homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors. J Steroid Btochem Mol Biol 1994 Nov: 51: 137-42
32. Kissmeyer A-M. Binderup L. Calcipotriol (MC-903): pharmacokinetics in rats and biological activities of metabolites - a comparative study with 1.25-dihydroxy vitamin D>. Biochem Pharmacol 1991 Jun 1: 41: 1601-6
33. Berth-Jones J. Bourke JF. Elouzi H. el al. Immediate and long term effects of topical calcipotriol on calcium homeostasis during treatment of psoriasis [abstract]. Br J Dermatol 1992 Jul: 127 Suppl. 40: 17-8
34. Saurai J-H. Sunek DC. Ri/zoli R. Topical calcipotriol and hypercalcaemia (letter]. Lancet 1991 May 25: 337: 1287
35. Morlensen L. Kragballe K. Wegmann E. et al. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, doubleblind, placebo-controlled study. Acta Derm Venereol 1993 Aug; 73: 300-4
36. Gumowski-Sunek D, Rizzoli R, Saurat J-H. Oral calcium tolerance test in extensive psoriasis treated with topical calcipotriol. Dermatology 1995; 190 (1): 43-7
37. Gumowski-Sunek D, Rizzoli R, Saurat J-H. Effects of topical calcipotriol on calcium metabolism in psoriatic patients: comparison with oral calcitriol. Dermatologica 1991 ; 183 (4): 275-9
38. Berth-Jones J, Bourke JF, Iqbal SJ, et al. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 1993 Oct; 129: 411-4
39. Arnold WP, van de Kerkhof PCM. The induction of epidermal ornithine decarboxylase following tape stripping is inhibited by a topical vitamin Di analogue (MC903). Br J Dermatol 1991 Jul; 125:6-8
40. Smith EL. Walworth NC, Holick MF. Effect of la,25dihydroxyvitamin D.î on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86: 709-14
41. Milde P, Hauser U, Simon T, et al. Expression of 1,25dihydroxyvitamin Dj receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97 (2): 230-9
42. Phillips WG, Breathnach SM. Psoriasis: immune indicators and treatment. Clin Immunother 1994 Feb; I: 157-67
43. Jack DB. Unravelling mechanisms of disease and treatment in psoriasis. Inpharma 1995 Sep; 9: 9-10
44. Oxholm A, Oxholm P, Staberg B, et al. Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). Acta Derm Venereol 1989; 69: 385-90
45. Reitamo S, Remitz A, Glorioso L, et al. Induction of IL-8 gene with cyclosporine and vitamin D in vilro [abstract]. Clin Res 1993 Apr;41:466A
46. Plow EF, Herren T, Redlitz A, et al. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-45
47. Bagot M, Charue D, Lèses M-C, et al. Immunosuppressive effects of 1,25-dihydroxyvitamin Di and its analogue calcipotriol on epidermal cells. Br J Dermatol 1994 Apr; 130: 424-31
48. Coffey Jr RJ, Bascom CC, Sipes NJ, et al. Selective inhibition of growth related gene expression in murine keratinocytes by transforming growth factor . Mol Cell Biol 1988; 8: 3088-93
49. Koli K, Keski-Oja J. Vitamin Dj regulation of transforming growth factor- system in epithelial and fibroblastic cells relationships to plasminogen activation. J Invest Dermatol 1996. In press
50. Bouillon R, Allewaert K, Xiang DZ, et al. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991 Oct; 6: 1051-7
51. Liao W-c. Kripalani K, Natarajan C, et al. Percutaneous absorption of -'H-calcipotriene ointment in healthy male volunteers and male psoriatic patients [abstract]. Clin Res 1993 Apr; 41 : 497A
52. Rougier A, Lotte C, Maibach HI. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: predictive assessment by the stripping melhod. J Pharm Sei 1986; 76 (6): 451-4
53. Sorensen H, Binderup L, Calverley MJ, et al. In vitro metabolism of calcipotriol (MC 903), a vitamin D analogue. Biochem Pharmacol 1990 Jan 15; 39: 391-3
54. Masuda S, Strugnell S, Calverley MJ, et al. In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem 1994 Feb 18:269:4794-803
55. Holick ME Will 1,25-dihydroxyvitamin D.., MC 903, and their analogues herald a new pharmacologie era for the treatment of psoriasis? [comment]. Arch Dermatol 1989 Dec; 125: 1692-7
56. Lewis HM. Therapeutic progress. U: Treatment of psoriasis. J Clin Pharm Ther 1994 Aug; 19: 223-32
57. Binderup L, Kragballe K. Origin of the use of calcipotriol in psoriasis treatment. Rev Contemp Pharmacother 1992; 3: 357-65
58. Greaves MW, Weinstein CD. Treatment of psoriasis. N Engl J Med 1995 Mar 2; 332: 581-8
59. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994 Apr; 130:483-7
60. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992 May; 26: 736-43
61. Fredriksson T, Lassus A, Salde L. Reproducibility of clinical trials of topical glucocorticosteroids. Int J Dermatol 1983; 22 (9): 536-9
62. Bourke JF, Berth-Jones J, Iqbal SJ. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993 Jul; 129:74-6
63. Bottomley WW, Jutley J, Wood EJ, et al. The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. ActaDerm Venereol Suppl Stockh 1995; 75: 363-6
64. Kiirkcuoglu N, Celebi CR. Confluent and reticulated papillomatosis: response to topical calcipotriol. Dermatology 1995; 191: 341-2
65. Berth-Jones J, Bourke J, Bailey K, et al. Generalised pustular psoriasis: response to topical calcipotriol. BMJ I992 Oct 10; 305: 868-9
66. Keohane SG, Cork MJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995 May; 132: 832-3
67. Gray JD, Bottomley W, Layton AM, et al. The use of calcipotriol in HIV-related psoriasis. Clin Exp Dermatol 1992 Sep; 17: 342-3
68. Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization: results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995 May; 131:556-60
69. Delfino M, Fabbrocini G, Sammarco E, et al. Efficacy of calcipotriol versus lactic acid cream in the treatment of lamellar and X-linked ichthyoses. J Dermatol Treat 1994 Sep; 5: 151 -2
70. tucker GPH, van de Kerkhof PCM, van Dijk MR, et al. Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol 1994 Oct; 131:546-50
71. Gatti S, Carrozzo AM, Orlandi A, et al. Treatment of inflammatory linear verrucous epidermal naevus with calcipotriol. Br J Dermatol 1995 May; 132: 837-9
72. Harwood CA, Sloane J, Cook MG, et al. Calcipotriol in mycosis fungoides [abstract]. Br J Dermatol 1995 Jul; 133 Suppl. 45: 43
73. Kokelj F, Lavaroni G, Piraccini BM, et al. Nail psoriasis treated with calcipotriol (MC 903): an open study. J Dermatol Treat I994Seu: 5: 149-50
74. van de Kerkhot'PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol 1994 May; 130: 675-8
75. Lucker GPH, van de Kerkhot'PCM, Cruysberg JRM, et al. Topical treatment of Sjögren-Larsson syndrome with calcipotriol. Dermatology 1995; 190(4): 292-4
76. Harrison PV. Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol [letter]. Clin Exp Dermatol 1994 Jan; 19: 95
77. Dubertret L. Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehiclecontrolled study. J Am Acad Dermatol 1992 Dec: 27 (Pt 1 ): 983-8
78. Harrington C. Austad J, Goldin D, et al. Efficacy and safety aspecls of calcipotriol cream in the treatment of psoriasis vulgaris [abstract]. Calcipotriol: a Vitamin D Analogue for the Treatment of Psoriasis. Satellite Symposium of the Third Congress of the European Academy of Dermatology and Venereologv Copenhagen, Sep 1993.
79. Highton A, Quell J, Calcipotriene SG. et al. Calcipotriene ointment ().005r/r for psoriasis: a safety and efficacy study. J Am Acad Dermatol 1995 Jan; 32: 67-72
80. Bruce S. Epinette WW, Funicella T, et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994 Nov: 31 (Pt 11:755-9
81. Klaber MR. Hutchinson PE, Pedvis-Leftick A. et al. Comparative effects of calcipotriol solution (50 n/ml) and betametha sone 17-valerate solution ( lmg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994 Nov: 1.31: 678-83
82. Kragballe K. Gjertsen B T. de Hoop D. et al. Double-blind, right/left comparison of calcipotriol and hetamethasone valerate in treatment ot psoriasis vulgaris. Lancet 1991 Jan 26: 337: 193-6
83. Berth Jones J. Chu AC. Dodd WAH, et al. A multicentre, parallel-group comparison of calcipotriol ointment and shortcontact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992 Sep: 127: 266-71
84. Tham SN. Lun KC. Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994 Nov; 131:673-7
85. Austad J. Treatment of psoriasis with calcipotriol + UVB light versus monotherapy with calcipotriol or UVB (abstract]. Calcipotriol in Combination with Phototherapy Satellite Symposium. 27th Nordic Dermatology Congress. Jun 1995.
86. FrappaJ. A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993 Jun-Jul: 3: 351-4 '
87. Grossman RM. Thivolet J. Claudy A. et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo controlled study. J Am Acad Dermatol 1994 Jul: 31: 68-74
88. Molin L. van Weelden H. Austad J. et al. Does UVB improve the effect of calcipotriol in psoriasis' [abstract]. Calcipotriol Rationale. Efficacy and Safety. Proceeding of the 2nd International Symposium on Calcipotriol. Monte Carlo, Mar 1993.
89. Ellis JP Griffiths WAD. Klaber MR. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short-contact dithranol. Eur J Clin Res 1995; 7: 247-57
90. Katz HI. Watson MJ. Long-term efficacy and safety of calcipotriol in the treatment of psoriasis vulgaris [abstract].
91. Calcipotriol: a Vitamin D Analogue tor the Treatment of Psoriasis. Satellite Symposium of the Third Congress of the European Academy of Dermatology and Venereology. Copenhagen, Sep 1993.
92. PoynerT. Hughes 1W. Dass BK, et al. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993 Dec; 4: 173-7
93. Ramsay CA, Berth-Jones J, Brundin G. et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189(3): 260-4
94. van de Kerkhol PCM. Calcipotriol cream and concurrent corticosteroids in psoriasis [abstract]. J Eur Acad Derm & Vener 1995; 5 Suppl. 1: S184
95. Harrington CI. Cost-effectiveness analysis of calcipotriol ointment and 'short-contact' dithranol in treating mild-to-moderate psoriasis. Br J Med Econ 1995; 8: 27-32
96. Darley CR. Cunliffe WJ, Ferguson J. et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris [abstract!. Br J Dermatol 1993 Juli 129 Suppl. 42: 33
97. Sulzberger MB. Willen VH. Thin pliable plastic strips in topical dermatologie therapy. Arch Dermatol 1961: 84: 1027-8
98. Shore RN. Clearing of psoriatic lesions after the application of tape [letter]. N Engl J Med 1985; 312: 246
99. Berardesca E. Maibach HI. Skin occlusive: treatment or druglike device'1 Skin Pharmacol 1988; 1: 207-15
100. David M. Lowe NJ. Psoriasis therapy: comparative studies w ith a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989; 21:511-4
101. Griffiths CE, Tranfaglia MG. Kang S. Prolonged occlusion in the treatment of psoriasis: a clinical and immunohistologic study. J Am Acad Dermatol 1995; 32 (4): 618-22
102. Bourke JF. Berth-Jones J. Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment ot psoriasis vulgaris. Clin Exp Dermatol 1993 Nov: 18: 504-6
103. Friedman SJ. Management ot psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 987; 123: 1046-52
104. Gottlieb AB. Staiano-Coico L. Cohen SR. et al. Occlusive hydrocolloid dressings decrease keratinocyte population growth traction and clinical scale and skin thickness in active psoriatic plaques. J Dermatol Sei 1990; I: 93-6
105. McKenna KE. Stern RS. Photosensitivity associated with combined UVB and calcipotriol therapy. Arch Dermatol 1995 Nov: 131: 1305-7
106. Kokelj F. Laxaroni G. Perkan V. et al. Hyperpigmentation due to calcipotriol (MC 903) plus heliotherapy in psoriatic patients. Acta Derm Venereol Suppl Stockh 1995: 75: 307-9
107. Lebvvohl MG. The evolution of vitamin D analogues for the treatment of psoriasis [editorial]. Arch Dermatol Res 1995: 131: 1323-4
108. Kragballe K. Safety aspects ol calcipotriol treatment [abstract). Acta Derm Venereol 1994 Suppl. 186: 44
109. Gumowski-Sunek D. Rizzoli R. Saurat J-H. Calcium tolerance test in patients with extended body surface psoriasis and treated with calcipotriol. Dermatology 1992; 185 (3): 229-30
110. Bourke JF. Berth-Jones J, Mumford R, et al. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels. Clin Endocrinol 1994 Sep: 41: 295-7
111. Jürgensen HJ. Tolerability and safely of calcipotriol ointment related lo palient characteristics [abstract|. Calcipotriol Rationale. Efficacy and Safety. Proceeding of the 2nd International Symposium on Calcipotriol. Monte Carlo, Mar 1993.
112. Clue to Dovonex irritation? [meeting report) Pharm J 1993 Apr 17:250:530
113. Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994 Mar; 235: 281-2
114. Dwyer C. Chapman RS. Calcipotriol and hypercalcaemia | letter]. Lancet 1991 Sep 21; 338: 764-5
115. Dovonex ointment (calcipotriol ). Curr Probl Pharmacovig 1994 Feb; 20: 3
116. McKenna KE, Burrows D. Hypercalciuria and topical calcipotriol therapy [letterl. Br J Dermatol 1994 Oct; 131: 588
117. Russell S, Young MJ. Hypercalcaemia during treatment of psoriasis with calcipotriol. Br J Dermatol 1994 Jun; 130: 795-6
118. Hardman K A, Heath DA. Nelson HM. Hypercalcaemia associated with calcipotriol (Dovonex) treatment |letter|. BMJ 1993 Apr 3; 306: 896
119. Yip J, Goodfield M. Contact dermatitis from MC 903, a topical vitamin Dj analogue. Contact Dermatitis 1991 Aug; 25: 139-40
120. Bruynzeel DP, Hoi CW, Nieboer C. Allergic contact dermatitis to calcipotriol [letter]. Br J Dermatol 1992 Jul; 127: 66
121. de Groot AC. Contact allergy to calcipotriol. Contact Dermatitis 1994 Apr; 30: 242-3
122. Steinkjer B. Contact dermatitis from calcipotriol. Contact Dermatitis 1994 Aug; 31: 122
123. Gcorgala S, Rigopoulos D, Aroni K, et al. Generalized pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol 1994 Jul; 33: 515-6
124. Calcipotriol - headaches. Bull SADRAC 1995 Apr No. 64
125. Gray J. Calcipotriol in psoriasis. Update 1994 Nov 1 ; 49: 548-52
126. Physician's Desk Reference. 49th ed. Montvale, New Jersey: Medical Economics Data Production Company, 1995: 2624
127. ABPI Data Sheet Compendium. London: Datapharm Publications Ltd. 1994:772-3
128. Salicylic acid inactivates calcipotriol. Presc Update 1994 5: 14
129. Data on file. Leo Pharmaceutical Products, Ballerup. Denmark, 1995.
130. Workshop of the Research Unit of the Royal College of Physicians of London. Guidelines for management of patients with psoriasis. BMJ 1991 Oct 5; 303: 829-35
131. Swerlick R A, Lawley TJ. Eczema, psoriasis, cutaneous infections, acne, and other common skin disorders. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. 13th ed. Vol. 1. New York: McGraw-Hill, 1994: 276
132. Simpson KR, Löwe NJ. Trends in topical psoriasis therapy. Int J Dermatol 1994 May; 33: 333-6
133. Finzi AF. The modern approach: new combined treatments for psoriasis. Acta Derm Venereol 1994 Suppl. 186: 105-6
134. Panconesi E, Lotti T. Steroids versus nonsteroids in the treatment of cutaneous inflammation: therapeutic modalities for office use. Arch Dermatol Res 1992 Nov; 284 Suppl. 1:37-41
135. Berth-Jones J. Prescribing in psoriasis. Practitioner 1994 Mar: 238:231-4
136. Poyner T. Calcipotriol for first-line treatment of psoriasis [let ter]. Update 1995 May 15; 50: 715